Mustang Bio Revamps Stock Sales Strategy with New Agreement

Mustang Bio (MBIO) has provided an update.

Mustang Bio, Inc. has entered into an agreement with H.C. Wainwright & Co. to potentially sell shares of its common stock at market prices. The company can sell shares up to $5.6 million under this new arrangement, subject to SEC regulations. Additionally, Mustang Bio terminated its previous sales agreement, effective June 5, 2024, which had allowed for the sale of up to $100 million in common stock. This strategic shift in its stock offering approach allows for sales at times and amounts of the company’s choosing, with a 3% commission to the managing firm.

See more data about MBIO stock on TipRanks’ Stock Analysis page.